Luo Dong, Liu Yunfei, Zhu Hongwei, Li Xia, Gao Wenzhe, Li Xinyu, Zhu Shaihong, Yu Xiao
Department of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Surg Endosc. 2020 Aug;34(8):3368-3374. doi: 10.1007/s00464-019-07107-z. Epub 2019 Sep 3.
Sigmoid colon cancer is a lethal disease and has a strong indication for surgery. Robotic-assisted surgery is one of the promising alternative treatment for this disease. Nowadays, the MicroHand S surgical system and the Da Vinci surgical system have been assembled in China. However, there is still no report to study the therapeutic effects of the two robotic-assisted surgical systems. Thus, the purpose of this study was to compare clinical and economic outcomes of patients with sigmoid colon cancer undergoing robot-assisted radical surgery via The MicroHand S or Da Vinci surgical system.
The clinical data of 45 patients with sigmoid colon cancer undergoing the MicroHand S or Da Vinci robotic-assisted surgery at The Third Xiangya Hospital of Central South University from January 2017 to January 2019 were retrospectively analyzed.
Twenty-one patients received MicroHand S robotic-assisted radical surgery and 24 patients received Da Vinci robot-assisted radical surgery. No significant differences were observed in terms of operation time, number of lymph node harvested, blood loss, intestinal exhaust time, time of oral feeding resumption, volume of abdominal cavity 24-h drainage, hospital stay, complication and rate of conversion, removal time of drainage tube and catheter between MicroHand S and Da Vinci group. However, the MicroHand S group had significantly lower hospitalization costs (P = 0.002) and shorter time to get out of bed after surgery (P = 0.04). In addition, no recurrence and metastases were observed in both groups during the follow-up.
In patients with sigmoid colon cancer, the Da Vinci surgical system did not show obvious clinical advantages compared to the MicroHand S surgical system in surgical outcomes. However, the MicroHand S surgical platform showed advantages in terms of the hospitalization costs and length of postoperative bedtime. The outcome of this study will probably result in a shift to the MicroHand S surgical system as treatment preference in China.
乙状结肠癌是一种致命疾病，手术指征明确。机器人辅助手术是该疾病一种有前景的替代治疗方法。目前，MicroHand S手术系统和达芬奇手术系统已在中国组装。然而，尚无研究比较这两种机器人辅助手术系统的治疗效果。因此，本研究旨在比较通过MicroHand S或达芬奇手术系统行机器人辅助根治性手术的乙状结肠癌患者的临床和经济结局。
回顾性分析2017年1月至2019年1月在中南大学湘雅三医院接受MicroHand S或达芬奇机器人辅助手术的45例乙状结肠癌患者的临床资料。
21例患者接受了MicroHand S机器人辅助根治性手术，24例患者接受了达芬奇机器人辅助根治性手术。MicroHand S组和达芬奇组在手术时间、淋巴结清扫数量、失血量、肠道排气时间、恢复经口进食时间、腹腔24小时引流量、住院时间、并发症及中转率、引流管和导尿管拔除时间方面均无显著差异。然而，MicroHand S组的住院费用显著更低（P = 0.002），术后下床时间更短（P = 0.04）。此外，随访期间两组均未观察到复发和转移。
对于乙状结肠癌患者，在手术结局方面，达芬奇手术系统与MicroHand S手术系统相比未显示出明显的临床优势。然而，MicroHand S手术平台在住院费用和术后卧床时间方面显示出优势。本研究结果可能会使中国在治疗选择上转向MicroHand S手术系统。
